Loading
A phase 2 trial of AL8326 40 mg in small-cell lung cancer, renal cell carcinoma and non-small-cell lung cancer, run by Advenchen Pharmaceuticals, LLC., now recruiting.
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment is a phase 2 interventional study registered as NCT05363280 by Advenchen Pharmaceuticals, LLC., with 80 participants planned, started 2022-11-01 and due to reach its primary completion in 2027-12. Interventions recorded: AL8326 40 mg, AL8326 60 mg and AL8326 80 mg--stopped.
Shares Advenchen Laboratories, Renal cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Advenchen Laboratories and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.